Keywords: GW Pharmaceuticals, Sativex, research, multiple sclerosis, cancer

GW reveals strong Sativex data in multiple sclerosis

Article | 14 September 2009

Print This

The UK’s GW Pharmaceuticals says that results from two clinical studies of Sativex, the firm’s lead cannabinoid product, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in